131 related articles for article (PubMed ID: 37370197)
1. Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial.
Monzo L; Girerd N; Duarte K; Ferreira JP; McMurray JJV; van Veldhuisen DJ; Swedberg K; Pocock SJ; Pitt B; Zannad F
Eur J Heart Fail; 2023 Aug; 25(8):1444-1449. PubMed ID: 37370197
[TBL] [Abstract][Full Text] [Related]
2. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
4. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
[TBL] [Abstract][Full Text] [Related]
5. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H;
Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642
[TBL] [Abstract][Full Text] [Related]
6. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Olivier A; Pitt B; Girerd N; Lamiral Z; Machu JL; McMurray JJV; Swedberg K; van Veldhuisen DJ; Collier TJ; Pocock SJ; Rossignol P; Zannad F; Pizard A
Eur J Heart Fail; 2017 Sep; 19(9):1186-1197. PubMed ID: 28303624
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
Cannon JA; Collier TJ; Shen L; Swedberg K; Krum H; Van Veldhuisen DJ; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
Eur J Heart Fail; 2015 Jul; 17(7):707-16. PubMed ID: 26139584
[TBL] [Abstract][Full Text] [Related]
8. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction.
Matsumoto S; Kondo T; Jhund PS; Campbell RT; Swedberg K; van Veldhuisen DJ; Pocock SJ; Pitt B; Zannad F; McMurray JJV
J Am Coll Cardiol; 2023 Sep; 82(11):1080-1091. PubMed ID: 37642608
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
Girerd N; Collier T; Pocock S; Krum H; McMurray JJ; Swedberg K; Van Veldhuisen DJ; Vincent J; Pitt B; Zannad F
Eur Heart J; 2015 Sep; 36(34):2310-7. PubMed ID: 26093641
[TBL] [Abstract][Full Text] [Related]
10. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
11. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F
Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240
[TBL] [Abstract][Full Text] [Related]
12. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
[TBL] [Abstract][Full Text] [Related]
14. Real world comparison of spironolactone and eplerenone in patients with heart failure.
Pardo-Martínez P; Barge-Caballero E; Bouzas-Mosquera A; Barge-Caballero G; Couto-Mallón D; Paniagua-Martín MJ; Sagastagoitia-Fornie M; Prada-Delgado Ó; Muñiz J; Almenar-Bonet L; Vázquez-Rodríguez JM; Crespo-Leiro MG
Eur J Intern Med; 2022 Mar; 97():86-94. PubMed ID: 35000806
[TBL] [Abstract][Full Text] [Related]
15. Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF).
Tsutsui H; Ito H; Kitakaze M; Komuro I; Murohara T; Izumi T; Sunagawa K; Yasumura Y; Yano M; Yamamoto K; Yoshikawa T; Tsutamoto T; Zhang J; Okayama A; Ichikawa Y; Kanmuri K; Matsuzaki M;
Circ J; 2017 Dec; 82(1):148-158. PubMed ID: 28824029
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
[TBL] [Abstract][Full Text] [Related]
17. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
Collier TJ; Pocock SJ; McMurray JJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
Eur Heart J; 2013 Sep; 34(36):2823-9. PubMed ID: 23864130
[TBL] [Abstract][Full Text] [Related]
18. Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial.
Ferreira JP; Lamiral Z; McMurray JJV; Swedberg K; van Veldhuisen DJ; Vincent J; Rossignol P; Pocock SJ; Pitt B; Zannad F
Circ Heart Fail; 2021 Jun; 14(6):e008075. PubMed ID: 34129365
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Higuchi H; Sai S; Nakatsukasa T; Sugano A; Baba M; Obara K; Aonuma K
Heart Vessels; 2019 Feb; 34(2):279-289. PubMed ID: 30203391
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
